Published in final edited form as:

Angew Chem Int Ed Engl. 2013 May 27; 52(22): 5757–5761. doi:10.1002/anie.201209991.

Supramolecular self-assembled nanoparticles mediate oral delivery of therapeutic TNF- α siRNA against systemic inflammation

Lichen Yin,

Department of Materials Science and Engineering University of Illinois, Urbana-Champaign 1304 W. Green Street, Urbana, IL 61801 (USA)

Ziyuan Song,

Department of Materials Science and Engineering University of Illinois, Urbana-Champaign 1304 W. Green Street, Urbana, IL 61801 (USA)

Qiu hao Qu,

Institute of Genomic Biology University of Illinois, Urbana-Champaign 1206 W. Gregory Drive, Urbana, IL 61801 (USA)

Kyung Hoon Kim,

Department of Materials Science and Engineering University of Illinois, Urbana-Champaign 1304 W. Green Street, Urbana, IL 61801 (USA)

Nan Zheng,

Department of Materials Science and Engineering University of Illinois, Urbana-Champaign 1304 W. Green Street, Urbana, IL 61801 (USA)

Catherine Yao,

Department of Materials Science and Engineering University of Illinois, Urbana-Champaign 1304 W. Green Street, Urbana, IL 61801 (USA)

Isthier Chaudhury,

Department of Materials Science and Engineering University of Illinois, Urbana-Champaign 1304 W. Green Street, Urbana, IL 61801 (USA)

Haoyu Tang,

Department of Materials Science and Engineering University of Illinois, Urbana-Champaign 1304 W. Green Street, Urbana, IL 61801 (USA)

Nathan P. Gabrielson,

Institute of Genomic Biology University of Illinois, Urbana-Champaign 1206 W. Gregory Drive, Urbana, IL 61801 (USA)

Fatih M. Uckun, and

Division of Hematology-Oncology, Systems Immunobiology Laboratory, Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA 90027 (USA)

Jianjun Cheng*

Department of Materials Science and Engineering University of Illinois, Urbana-Champaign 1304 W. Green Street, Urbana, IL 61801 (USA)

* Fax: (+1) 217-333-2736 jianjunc@illinois.edu; Homepage: <http://cheng.matse.illinois.edu/>.

Keywords

oral siRNA delivery; TNF- α ; inflammation; supramolecular self-assembly; multi-function

Intervention of the inflammation cascade with tumor necrosis factor- α (TNF- α) monoclonal antibodies or receptors represents a major approach in clinical immunotherapy against inflammatory diseases, which however, often suffers from high cost, autoimmunity to antibodies, and various side effects.^[1] siRNA-mediated RNA interference (RNAi) has recently emerged as a potent modality in regulating gene expression by suppressing mRNA translation;^[2-13] its high efficiency and specificity has made it a promising treatment paradigm for TNF- α -mediated inflammatory disorders.^[14-18] The therapeutic potential of siRNA was recently exemplified by a report of attenuating systemic inflammation by targeting orally delivered Map4k4 siRNA to gut-associated macrophages (GAMs).^[19] Owing to the infiltration of GAMs to systemic reticuloendothelial tissues, Map4k4 siRNA-mediated TNF- α knockdown in GAMs extended to other tissues and thus induced systemic anti-inflammatory effects.^[19]

Despite its biological potency, the clinical potential of orally delivered siRNA has been hampered by the lack of efficient delivery technologies. siRNA is anionic, hydrophilic, and easily degraded by nucleases in the body. As such, it cannot survive the harsh condition of the gastrointestinal (GI) tract or effectively penetrate the intestinal epithelia or membranes of target cells.^[20, 21] Hence, an effective carrier is needed not only to protect siRNA from degradation in the GI tract but also to improve the intestinal absorption as well as transfection in macrophages,^[22] thereby maximizing the *in vivo* RNAi efficiency and anti-inflammatory effect of orally delivered siRNA.

To address the dearth of oral siRNA delivery technology, here we report the design of supramolecular self-assembled nanoparticles (SSNPs) that are able to overcome the absorption and transfection barriers posed by intestinal macrophages and exhibit remarkable *in vivo* oral RNAi efficiency. SSNPs were constructed via the electrostatic and hydrophobic self-assembly of several rationally designed or selected building blocks,^[23] including oleyl trimethyl chitosan (OTMC), poly(4-(((2-(piperidin-1-yl)ethyl)amino)methyl)benzyl-L-glutamate) (PVBLG-8), oleyl-PEG-mannose (OPM), oleyl-PEG-cysteamine (OPC), sodium tripolyphosphate (TPP), and TNF- α siRNA (Fig. 1A).

Trimethyl chitosan (TMC) is as an effective intestinal absorption enhancer as well as transfection reagent.^[24] As a more hydrophobic derivative of TMC, OTMC with the oleyl conjugation ratio of 20.3% was synthesized and expected to display further enhanced permeation-enhancing and gene transfection capabilities.^[25] PVBLG-8 is a cationic α -helical polypeptide we recently developed^[26, 27] which exhibits potent membrane activities and gene delivery efficiencies. We incorporated PVBLG-8 (degree of polymerization (DP) = 195) into the SSNPs in attempts to promote the cellular internalization and endosomal escape. PVBLG-8 adopts super-stable α -helix between pH 2 and 9 (Supplementary Fig. S2), making it an ideal material for oral delivery applications as it is able to maintain helical secondary structure after passing through both stomach (acidic) and intestinal (weak basic) environments. Incorporating OPM is expected to target SSNPs to enterocytes and macrophages that express mannose receptors,^[28] thus improving the intestinal absorption and macrophage uptake. OPC will improve the mucoadhesion of SSNPs by forming disulfide bonds with mucin glycoproteins enriched in the intestinal mucosa and on cell surfaces.^[29] OPM and OPC were synthesized by the conjugation methods and their structures were confirmed by MALDI-TOF-MS (Supplementary Fig. S3-S4). The 2'-O-methyl-modified siRNA duplex against TNF- α was reported previously,^[14, 30] wherein the

2-*O*-methyl modification on the anti-sense strand eliminates off-target effects, minimizes nonspecific immune responses, and improves siRNA stability. With these building blocks, SSNPs are expected to promote the intestinal absorption of TNF- α siRNA, facilitate RNAi in macrophages, and thus mediate systemic TNF- α knockdown against lipopolysaccharide (LPS)-induced hepatic injury.

For the construction of SSNPs, TNF- α siRNA was condensed with cationic OTMC and PVBLG-8 via electrostatic interactions at the OTMC/PVBLG-8/siRNA ratio of 100:20:1 (w/w). TPP, incorporated at an optimized TPP/OTMC ratio of 1:8 (w/w) (Supplementary Fig. S5), served as an anionic cross-linker for OTMC to stabilize the complexes.^[31] OPM and OPC were incorporated via intermolecular hydrophobic interactions with OTMC at a fixed ratio of 1:1:1 (w/w/w). The resulting SSNPs had a particle size of 128 nm, zeta potential of 33 mV, and spherical morphology (Fig. 1B and 1C). siRNA incorporation into the SSNPs was confirmed by a gel retardation assay, which revealed restricted migration of siRNA (Supplementary Fig. S6). When PVBLG-8, OPM, or OPC was removed from SSNPs, particle size and zeta potential remained unchanged (Fig. 1C), allowing comparison of the biological functions of SSNPs with their PVBLG-8-, OPM-, or OPC-depleted analogues.

The intestinal absorption of SSNPs and the associated mechanisms were examined in two *in vitro* models. The non-follicle-associated epithelia (non-FAE) model, obtained from monocultured Caco-2 cell monolayers, has been widely used as an *in vitro* intestinal epithelia model because the cultured Caco-2 cells differentiate into polarized, columnar cells and transporting epithelium with well-developed microvilli.^[32] The FAE model, obtained from Caco-2 cell monolayers co-cultured with Raji B lymphocytes, additionally contains a distinctive M cell phenotype.^[33] We monitored the apparent permeability coefficient (P_{app}) of Cy3-siRNA in these two models which represented the intestinal transport level. SSNPs enhanced siRNA transport in both models by 15-18 fold (Fig. 2A), which accorded well with their deeper penetration into the cell monolayers (Fig. 2B). Quantitative analysis of the images confirmed an increased siRNA penetration depth from 3.2 μ m (naked siRNA) to 33.8 μ m (SSNPs) (Fig. 2C). We further noted 2.9-fold increment of siRNA transport in the FAE-model compared to that in the non-FAE model for SSNPs (Fig. 2A), suggesting that a large proportion of the SSNPs were absorbed via transcellular uptake by M cells (pathway I, Fig. 2G), the most rapid and potent translocation pathway during intestinal absorption.

In addition to M cell uptake, we also evaluated the involvement of two other pathways, intracellular uptake by normal enterocytes (pathway II, Fig. 2G) and paracellular transport via tight junctions (TJs, pathway III, Fig. 2G). As shown in Fig. 2D and Supplementary Fig. S7, addition of the SSNPs at the apical side of the monolayers rapidly decreased the transepithelial electric resistance (TEER) values, suggesting that SSNPs opened the TJs to facilitate paracellular siRNA transport. The underlying mechanisms were explored by immunostaining the TJ-associated proteins (TJAPs), F-actin and ZO-1. Untreated cell monolayers showed uniformly distributed F-actin and continuous cell frame distribution of ZO-1 proteins (control, Fig. 2E, Supplementary Fig. S8 and S9). Upon treatment of SSNPs, F-actin filaments were redistributed, shortened, and aggregated, and ZO-1 proteins appeared to be loosened and discontinuous (SSNPs), indicating that the SSNPs triggered the reconfiguration of TJAPs and opened the TJs.^[34] After removal of SSNPs and further incubation for 24 h, the ZO-1 and F-actin patterns recovered to the untreated state (control), indicating reversible opening and restoration of epithelial TJs. In the non-FAE model containing only normal enterocytes, SSNPs markedly promoted the uptake of Cy3-siRNA (Fig. 2F), suggesting that SSNPs enhanced the transcellular uptake of siRNA by normal enterocytes. In these experiments, we noted significantly decreased siRNA transport and uptake in both models when PVBLG-8, OPM, or OPC were removed from the SSNPs (Fig. 2A and Fig. 2F). This observation validated our hypothesis that intestinal absorption of

siRNA could be improved by OPM-mediated targeting of SSNPs to enterocytes and M cells, OPC-mediated intestinal mucoadhesion (Supplementary Fig. S10), and PVBLG-8-mediated membrane permeation.

Since macrophages are the target cells for TNF- α siRNA-mediated gene silencing, we then explored the intracellular delivery and RNAi efficiency of SSNPs in RAW 264.7 cells. SSNPs markedly increased Cy3-siRNA uptake levels (Fig. 3A), and internalized Cy3-siRNA was observed in the cytoplasm (Fig. 3C). When PVBLG-8, OPM, or OPC was removed from SSNPs, the siRNA uptake level was significantly reduced, supporting our design strategy of enhancing macrophage uptake via PVBLG-8-mediated membrane penetration, OPM-mediated mannose-receptor recognition, and OPC-mediated cell binding. The mannose-receptor mediated targeting effect was further verified by the reduced siRNA uptake level when free mannose was added to competitively occupy the mannose receptors (Fig. 3A). Because RNAi efficiency is closely related to the intracellular kinetics, we also probed the internalization pathways of SSNPs using various endocytic inhibitors.^[35] NaN₃/deoxyglucose (DOG) substantially reduced the uptake of SSNPs, suggesting that they were mainly internalized via energy-dependent endocytosis (Fig. 3B). The caveolae inhibitors methylated- β -cyclodextrin (m-CD) and genistein and macropinocytosis inhibitor wortmannin^[35] significantly suppressed SSNPs uptake, indicating that both caveolae and macropinocytosis were involved in endocytosis. In contrast, chlorpromazine exerted unappreciable inhibitory effect, suggesting irrelevance to clathrin-mediated endocytosis.^[35] For further validation, we co-incubated Cy3-siRNA-containing SSNPs with transferrin-Alexa Fluor 635 or FITC-cholera toxin B (FITC-CTB) which are endocytosed via clathrin- and caveolae-mediated pathways, respectively.^[35] CLSM analysis showed that internalized SSNPs co-localized with CTB (Fig. 3E) rather than with transferrin (Fig. 3D), which confirmed the caveolae pathway for SSNPs uptake. As a result of the efficient cellular uptake, SSNPs inhibited LPS-induced TNF- α production in RAW 264.7 cells by ~90% at 0.1 μ g/mL (Fig. 3F and 3G). In agreement with the decreased uptake level, omission of PVBLG-8, OPM, or OPC from SSNPs resulted in a significant decrease in TNF- α knockdown efficiency. More noteworthy, SSNPs markedly outperformed Lipofectamine 2000 (LPF2000), exhibiting similar efficacy at a siRNA dose 10-fold less than LPF2000 (Fig. 3H) and 20~100-fold less than other non-viral vectors reported.^[15-17, 36]

The ability of orally administered SSNPs to mediate systemic TNF- α knockdown and anti-inflammatory effect was evaluated in LPS/D-GalN-induced murine hepatic injury model. The stability of SSNPs was first evaluated under simulated conditions. To mimic the pH change in the GI tract, the pH of SSNPs was adjusted from 6.8 (intestinal pH) to 1.2 (gastric pH) and then back to 6.8. Size and zeta potential of the SSNPs was unaffected by pH changes (Supplementary Fig. S14), suggesting their stability during transit through the GI tract. Likewise, dilution of SSNPs with 0.15 M PBS (pH 6.8) up to 100-fold resulted in unappreciable change in their sizes or zeta potentials (Supplementary Fig. S15), indicating that SSNPs can withstand the extensive dilution by physiological fluids. Following treatment with mouse serum or intestinal fluids, SSNPs effectively preserved the siRNA integrity (Supplementary Fig. S16), substantiating their desired resistance against nuclease attack. The biodistribution profiles of orally delivered SSNPs were then evaluated by using DY800-siRNA. SSNPs-treated mice experienced notably higher siRNA distribution levels in the liver, spleen, and lung than mice receiving naked siRNA (Fig. 4A). Combined with the observation of a ~20-fold higher siRNA level in the small intestine, it was demonstrated that SSNPs promoted both intestinal absorption and systemic translocation of siRNA. Single gavage of SSNPs at 200 μ g TNF- α siRNA/kg reduced mouse serum TNF- α levels by 80% (Fig. 4B) and notably depleted TNF- α mRNA in macrophage-enriched organs (liver, spleen, and lung; Fig. 4C), which suggested that the intestinally absorbed SSNPs had infiltrated and transfected macrophages in reticuloendothelial tissues to induce systemic TNF- α

knockdown.^[19] In accordance with the intestinal absorption levels and *in vitro* RNAi efficiencies, SSNPs without OPM, OPC, or PVBLG-8 showed significantly reduced *in vivo* silencing efficiency (Fig. 4B and 4C), again substantiating the essential roles of individual components in mediating oral absorption and systemic gene knockdown. As a result of systemic TNF- α knockdown, orally delivered SSNPs displayed marked anti-inflammatory effects against LPS/D-GalN-induced acute hepatic injury. LPS/D-GalN challenge elevated serum alanine transaminase (ALT) and aspartate aminotransferase (AST) levels (Fig. 4D), and caused animal lethality within 12 h (Fig. 4E). Comparatively, SSNPs orally administered 24 h before LPS/D-GalN stimulation significantly inhibited the elevation in serum ALT/AST levels and improved the survival rate. During necropsy, we noticed that livers from control mice (only LPS/D-GalN treated) turned yellow or black, indicating severe lipid accumulation, liver steatosis, and hemorrhage. While for SSNPs-treated mice, most of the livers remained normal reddish color, suggesting alleviation of the hepatic injury. Histological observation on HE-stained liver sections further confirmed the remarkable therapeutic efficacy of SSNPs in alleviating inflammatory symptoms, including congested central vein, infiltrated inflammatory cells, disarranged hepatocytes, and broken cytollemma (Fig. 4F). It was also noted that 24 h following oral administration of SSNPs, serum IL-1 β , IL-6, TNF- α , and IFN- γ levels were not significantly increased (Supplementary Fig. S19), indicating the SSNPs and TNF- α siRNA did not activate pro-inflammatory cytokines or induce IFN- γ responses.

Single gavage of SSNPs to induce marked TNF- α silencing at a low dose of 200 μ g siRNA/kg demonstrated comparable efficacy to previously reported α -1,3-D-glucan particles (GeRPs), which required a cumulative dose of 160 μ g siRNA/kg via oral administration within eight consecutive days.^[19] For clinical application, oral administration is clearly superior to i.p. or i.v. injections for existing siRNA delivery systems in treating TNF- α -associated hepatic injury.^[37, 38] Although oral RNAi against TNF- α has been reported to treat bowel inflammation,^[16, 18, 39] the gene knockdown was localized intestinally rather than infiltrated systemically, presumably due to inefficient intestinal absorption. Therefore, SSNPs that mediate effective intestinal absorption and systemic TNF- α silencing rendered obvious advantages. A relative pharmacological bioavailability of ~10% was noted compared to i.v. injection (comparable TNF- α silencing efficiency oral gavaged at 200 μ g siRNA/kg and i.v. administered at 20 μ g siRNA/kg, Supplementary Fig. S17), which suggested that oral administration represented a desired delivery route for systemic TNF- α silencing using multifunctional SSNPs. After SSNPs were intestinally absorbed by M cells, they could be directly transferred to the underlying GAMs which infiltrated systemic reticuloendothelial tissues to exert systemic gene knockdown.^[19] With the OTMC/OPC-mediated mucoadhesion and OPM-mediated mannose-targeting, SSNPs could be efficiently taken up by M cells and thereafter be directed to the underlying GAMs. Their excellent gene silencing capability thus allowed potent TNF- α knockdown in GAMs and macrophages enriched in the liver, spleen, and lung, ultimately leading to systemic TNF- α depletion.

In summary, we rationally designed and developed multifunctional SSNPs using a supramolecular self-assembly approach to incorporate materials with specific functions of mucoadhesion, trans-epithelial permeation, membrane penetration, and active targeting, which collectively contributed to effective circumvention of the various gastrointestinal, systemic, and cellular barriers toward oral RNAi. To the best of our knowledge, no other nanoparticle-based delivery vehicle has been so far reported to possess all of these attributes, making SSNPs the first example of a nanocarrier that simultaneously addresses the material requirements for mediating effective oral RNAi with a siRNA dose as low as 50 μ g/kg (Supplementary Fig. S18). The potent RNAi efficiency of SSNPs against systemic TNF- α production provides an exciting approach for the treatment of hepatic injury and other inflammatory diseases.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

J.C. acknowledges support from the NSF (CHE-1153122) and the NIH (NIH Director's New Innovator Award 1DP2OD007246 and 1R21EB013379).

References

1. Dulsat C, Mealy N. *Drugs of the Future*. 2009; 34:352.
2. Davis ME, Zuckerman JE, Choi CHJ, Seligson D, Tolcher A, Alabi CA, Yen Y, Heidel JD, Ribas A. *Nature*. 2010; 464:1067. [PubMed: 20305636]
3. Lee H, Lytton-Jean AKR, Chen Y, Love KT, Park AI, Karagiannis ED, Sehgal A, Querbes W, Zurenko CS, Jayaraman M, Peng CG, Charisse K, Borodovsky A, Manoharan M, Donahoe JS, Truelove J, Nahrendorf M, Langer R, Anderson DG. *Nat Nanotechnol*. 2012; 7:389. [PubMed: 22659608]
4. Woodrow KA, Cu Y, Booth CJ, Saucier-Sawyer JK, Wood MJ, Saltzman WM. *Nat Mater*. 2009; 8:526. [PubMed: 19404239]
5. Kim JH, Noh Y-W, Heo MB, Cho MY, Lim YT. *Angew Chem Int Edit*. 2012; 51:9670.
6. Jayaraman M, Ansell SM, Mui BL, Tam YK, Chen J, Du X, Butler D, Eltepu L, Matsuda S, Narayanannair JK, Rajeev KG, Hafez IM, Akinc A, Maier MA, Tracy MA, Cullis PR, Madden TD, Manoharan M, Hope MJ. *Angew Chem Int Edit*. 2012; 51:8529.
7. Lee SJ, Huh MS, Lee SY, Min S, Lee S, Koo H, Chu JU, Lee KE, Jeon H, Choi Y, Choi K, Byun Y, Jeong SY, Park K, Kim K, Kwon IC. *Angew Chem Int Edit*. 2012; 51:7203.
8. Shim MS, Bhang SH, Yoon K, Choi K, Xia Y. *Angew Chem Int Edit*. 2012; 51:11899.
9. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H. *Nat Genet*. 2002; 32:107. [PubMed: 12145662]
10. Xia HB, Mao QW, Paulson HL, Davidson BL. *Nat Biotechnol*. 2002; 20:1006. [PubMed: 12244328]
11. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO, Giangrande PH. *Nat Biotechnol*. 2009; 27:839. [PubMed: 19701187]
12. Lee JB, Hong J, Bonner DK, Poon Z, Hammond PT. *Nat Mater*. 2012; 11:316. [PubMed: 22367004]
13. Alvarez-Erviti L, Seow YQ, Yin HF, Betts C, Lakhal S, Wood MJA. *Nat Biotechnol*. 2011; 29:341. [PubMed: 21423189]
14. Howard KA, Paludan SR, Behlke MA, Besenbacher F, Deleuran B, Kjems J. *Mol Ther*. 2009; 17:162. [PubMed: 18827803]
15. Kim SS, Ye CT, Kumar P, Chiu I, Subramanya S, Wu HQ, Shankar P, Manjunath N. *Mol Ther*. 2010; 18:993. [PubMed: 20216529]
16. Wilson DS, Dalmaso G, Wang LX, Sitaraman SV, Merlin D, Murthy N. *Nat Mater*. 2010; 9:923. [PubMed: 20935658]
17. Lee S, Yang SC, Kao CY, Pierce RH, Murthy N. *Nucleic Acids Res*. 2009; 37.
18. Kriegel C, Amiji M. *J Control Release*. 2011; 150:77. [PubMed: 20959130]
19. Aouadi M, Tesz GJ, Nicoloso SM, Wang MX, Chouinard M, Soto E, Ostroff GR, Czech MP. *Nature*. 2009; 458:1180. [PubMed: 19407801]
20. Bowman K, Sarkar R, Raut S, Leong KW. *J Control Release*. 2008; 132:252. [PubMed: 18634839]
21. Ensign LM, Cone R, Hanes J. *Adv Drug Deliver Rev*. 2012; 64:557.
22. Roy K, Mao HQ, Huang SK, Leong KW. *Nat Med*. 1999; 5:387. [PubMed: 10202926]
23. Wang H, Wang ST, Su H, Chen KJ, Armijo AL, Lin WY, Wang YJ, Sun J, Kamei K, Czernin J, Radu CG, Tseng HR. *Angew Chem Int Edit*. 2009; 48:4344.

24. Sonia TA, Sharma CP. Chitosan for Biomaterials I. 2011; 243:23.
25. Gabrielson NP, Cheng JJ. Biomaterials. 2010; 31:9117. [PubMed: 20813404]
26. Lu H, Wang J, Bai Y, Lang JW, Liu S, Lin Y, Cheng J. Nat Commun. 2011; 2:206. [PubMed: 21343924]
27. Gabrielson NP, Lu H, Yin LC, Li D, Wang F, Cheng JJ. Angew Chem Int Edit. 2012; 51:1143.
28. Fievez V, Plapied L, des Rieux A, Pourcelle V, Freichels H, Wascotte V, Vanderhaeghen ML, Jerome C, Vanderplasschen A, Marchand-Brynaert J, Schneider YJ, Preat V. Eur J Pharmaceut Biopharmaceut. 2009; 73:16.
29. Yin LC, Ding JY, He CB, Cui LM, Tang C, Yin CH. Biomaterials. 2009; 30:5691. [PubMed: 19615735]
30. Amarzguioui M, Lundberg P, Cantin E, Hagstrom J, Behlke MA, Rossi JJ. Nat Protoc. 2006; 1:508. [PubMed: 17406276]
31. Katas H, Alpar HO. J Control Release. 2006; 115:216. [PubMed: 16959358]
32. Kadiyala I, Loo YH, Roy K, Rice J, Leong KW. Eur J Pharm Sci. 2010; 39:103. [PubMed: 19913612]
33. Loo YH, Grigsby CL, Yamanaka YJ, Chellappan MK, Jiang X, Mao HQ, Leong KW. J Control Release. 2012; 160:48. [PubMed: 22326811]
34. Lin YH, Sonaje K, Lin KM, Juang JH, Mi FL, Yang HW, Sung HW. J Control Release. 2008; 132:141. [PubMed: 18817821]
35. Khalil IA, Kogure K, Akita H, Harashima H. Pharmacol Rev. 2006; 58:32. [PubMed: 16507881]
36. Dong L, Xia SH, Luo Y, Diao HJ, Zhang J, Chen JN, Zhang JF. J Control Release. 2009; 134:214. [PubMed: 19073226]
37. Lundberg P, Yang HJ, Jung SJ, Behlke MA, Rose SD, Cantin EM. J Control Release. 2012; 160:194. [PubMed: 22094102]
38. Un K, Kawakami S, Yoshida M, Higuchi Y, Suzuki R, Maruyama K, Yamashita F, Hashida M. Hepatology. 2012; 56:259. [PubMed: 22271390]
39. Laroui H, Theiss AL, Yan YT, Dalmaso G, Nguyen HTT, Sitaraman SV, Merlin D. Biomaterials. 2011; 32:1218. [PubMed: 20970849]

Figure 1. (A) Schematic illustration, (B) SEM image, and (C) particle size and zeta potential of SSNPs (bar = 200 nm in SEM image).

Figure 2. Intestinal absorption of Cy3-siRNA-containing SSNPs. (A) P_{app} of Cy3-siRNA across human non-FAE and FAE models ($n = 3$). (B) CLSM images showing cross-sections of the FAE model at 5- μ m increments in the Z direction following SSNPs treatment for 4 h (bar = 20 μ m). (C) Penetration depth of Cy3-siRNA in the FAE model. (D) TEER of the FAE model following incubation with SSNPs ($n = 3$). (E) CLSM images of the FAE model stained for ZO-1 after treatment with SSNPs (bar = 20 μ m). (F) Uptake of SSNPs in the non-FAE model following 4-h incubation ($n = 3$). (G) Intestinal absorption pathways of SSNPs, including transcellular transport by M cells (pathway I), uptake by normal enterocytes (pathway II), and paracellular transport via transiently opened tight junctions

(pathway **III**). The absorbed SSNPs were transferred either to GAMs or to systemic circulation.

Figure 3.

SSNPs deliver TNF- α siRNA to macrophages via mannose receptor-mediated endocytosis and attenuate TNF- α production *in vitro*. (A) Uptake of Cy3-siRNA-containing SSNPs in RAW 264.7 cells following incubation for 4 h ($n = 3$). (B) Uptake of SSNPs in RAW 264.7 cells in the presence of various endocytosis inhibitors ($n = 3$). (C) CLSM images showing internalization of Cy3-siRNA-containing SSNPs in RAW 264.7 cells. Cy3-siRNA-SSNPs co-localized with FITC-CTB (D, white arrows) rather than with transferrin-Alexa Fluor 635 (E) (bar = 10 μ m). TNF- α (F) and TNF- α mRNA levels (G) of RAW 264.7 cells following treatment with SSNPs at 0.1 μ g siRNA/mL. (H) Comparison on the TNF- α knockdown efficiencies of SSNPs and LPF2000/siRNA complexes at various siRNA doses ($n = 3$).

Figure 4.

Orally delivered SSNPs mediate efficient RNAi against LPS-induced TNF- α production and protected mice from acute hepatic injury. (A) Biodistribution of DY800-siRNA 2 h post oral gavage of SSNPs or naked DY800-siRNA ($n = 3$). (B) Serum TNF- α level of mice gavaged with SSNPs at 200 μg siRNA/kg ($n = 6$). (C) Relative TNF- α mRNA levels in mouse liver, spleen, and lung 24 h after oral gavage of SSNPs ($n = 3$). (D) Serum ALT and AST levels of mice 5 h after LPS/D-GalN stimulation ($n = 4$). (E) Survival of mice following oral gavage of SSNPs and i.p. injection of LPS/D-GalN 24 h later ($n = 10$). (F) HE-stained liver sections from mice 5 h after LPS/D-GalN stimulation (bar = 1 mm).